AloCELYVIR
Phase 2Biologic
AloCELYVIR is one of 16 biologic programs targeting Diffuse Intrinsic Pontine Glioma. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Diffuse Intrinsic Pontine Glioma
#DrugCompanyPhaseTrials
1Verzenio
Eli LillyApproved
Caprelsa
GGenzyme, a Sanofi Company
Approved
Aldara
BBausch Health Americas, Inc.
Approved
Farydak
SSecuraBio
Approved
Avastin
RochePhase 2
Adriamycin
PfizerPhase 2
ONC201
Jazz PharmaceuticalsPhase 3
Rituxan
RochePhase 1
Fludara
SanofiPhase 1
Paxalisib
KKazia Therapeutics Limited
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Diffuse Intrinsic Pontine Glioma1 trial
Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy
Active, not recruiting·HHospital Infantil Universitario Niño Jesús, Madrid, Spain·Phase 1/2·NCT04758533·13 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AloCELYVIR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details